Trial Profile
The Physiological and Cardiovascular Effects of Empagliflozine in Type 2 Diabetes
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms EMP
- 10 Oct 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2018.
- 10 Oct 2017 Planned initiation date changed from 1 Oct 2016 to 1 Nov 2017.